Table 7. Prevalence of molecular variants associated with resistance to sulfadoxine-pyrimethamine and amodiaquine, from survey samples at the end of the transmission season.
| Variant | CCM | SMC+CCM | Difference (95% CI) | p-Value | ||
|---|---|---|---|---|---|---|
| Number positive/number typed | Prevalence (95% CI) | Number positive/number typed | Prevalence (95% CI) | |||
| pfmdr1-86Y | 5/140 | 0.04 (0.00, 0.07) | 6/42 | 0.14 (0.04, 0.24) | 0.11 (0.00, 0.21) | 0.044 |
| pfmdr1-184Y | 96/140 | 0.69 (0.62, 0.75) | 24/42 | 0.57 (0.49, 0.65) | −0.11 (−0.22, −0.01) | 0.037 |
| pfmdr1-1246Y | 1/140 | 0.01 (−0.01, 0.02) | 0/42 | 0.00 (0.00, 0.00) | −0.01 (−0.02, 0.01) | 0.297 |
| pfdhfr-51I | 91/140 | 0.65 (0.56, 0.74) | 21/30 | 0.70 (0.62, 0.78) | 0.05 (−0.07, 0.17) | 0.393 |
| pfdhfr-59R | 92/140 | 0.66 (0.60, 0.72) | 20/30 | 0.67 (0.53, 0.80) | 0.01 (−0.14, 0.16) | 0.895 |
| pfdhfr-108N | 100/140 | 0.71 (0.65, 0.77) | 22/30 | 0.73 (0.63, 0.84) | 0.02 (−0.10, 0.14) | 0.738 |
| pfdhps-436A | 45/140 | 0.32 (0.22, 0.42) | 11/42 | 0.26 (0.11, 0.41) | −0.06 (−0.24, 0.12) | 0.505 |
| pfdhps-437A | 65/140 | 0.46 (0.34, 0.59) | 19/42 | 0.45 (0.22, 0.68) | −0.01 (−0.27, 0.25) | 0.926 |
| pfdhps-613S | 3/140 | 0.02 (0.00, 0.05) | 4/42 | 0.10 (0.04, 0.15) | 0.07 (0.02, 0.13) | 0.016 |
| pfmdr1 haplotypes 86, 184, 1246 | ||||||
| YYD | 2/139 | 0.01 (0.00, 0.03) | 0/42 | 0.00 (0.00, 0.00) | −0.01 (−0.03, 0.01) | 0.148 |
| YND | 3/139 | 0.02 (0.00, 0.05) | 6/42 | 0.14 (0.04, 0.24) | 0.12 (0.02, 0.22) | 0.024 |
| NYY | 1/139 | 0.01 (0.00, 0.02) | 0/42 | 0.00 (0.00, 0.00) | −0.01 (−0.02, 0.01) | 0.296 |
| NYD | 93/139 | 0.67 (0.60, 0.73) | 24/42 | 0.57 (0.49, 0.65) | −0.10 (−0.20, 0.01) | 0.067 |
| NND | 47/139 | 0.34 (0.27, 0.41) | 13/42 | 0.31 (0.20, 0.42) | −0.03 (−0.16, 0.10) | 0.658 |
| pfdhfr-51I+59R+108N | 68/123 | 0.55 (0.46, 0.64) | 19/29 | 0.66 (0.52, 0.79) | 0.10 (−0.06, 0.26) | 0.194 |
| pfdhps haplotypes 431, 436, 437, 540, 581, 613 | ||||||
| IAAKAA | 28/132 | 0.21 (0.14, 0.28) | 6/42 | 0.17 (0.06, 0.27) | −0.05 (−0.17, 0.08) | 0.467 |
| IAGKAA | 8/132 | 0.06 (0.02, 0.10) | 1/42 | 0.02 (−0.02, 0.07) | −0.04 (−0.10, 0.03) | 0.239 |
| IAGKAS | 1/132 | 0.01 (−0.01, 0.02) | 3/42 | 0.07 (0.01, 0.14) | 0.06 (0.00, 0.13) | 0.062 |
| ISAKAA | 34/132 | 0.26 (0.17, 0.35) | 12/42 | 0.29 (0.13, 0.45) | 0.03 (−0.16, 0.21) | 0.753 |
| ISGKAA | 72/132 | 0.55 (0.42, 0.67) | 19/42 | 0.45 (0.28, 0.63) | −0.09 (−0.31, 0.13) | 0.386 |
| ISGKAS | 1/132 | 0.01 (−0.01, 0.02) | 1/42 | 0.02 (−0.02, 0.07) | 0.02 (−0.03, 0.06) | 0.469 |
CCM, community case management; SMC, seasonal malaria chemoprevention.